Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model

Neoplasia

Volumn 13, Issue 8, 2011, Pages 692-703

  Birbach, Andreas ^a   Eisenbarth, David ^a   Kozakowski, Nicolas ^a   Ladenhauf, Eva ^a   Schmidt Supprian, Marc ^b   Schmid, Johannes A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; I KAPPA B KINASE; I KAPPA B KINASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER INVASION; DOWN REGULATION; ENZYME ACTIVATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; INFLAMMATION; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE TUMOR; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; STROMA; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

EID: 80051535218     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11524     Document Type: Article

References (42)

1. Kuper H, Adami HO, and Trichopoulos D (2000). Infections as a major preventable cause of human cancer. J InternMed 248, 171-183.
2. Grivennikov SI, Greten FR, and Karin M (2010). Immunity, inflammation, and cancer. Cell 140, 883-899.
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, and Nelson WG (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer 7, 256-269.
4. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, and Gupta S (2006). The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 176, 1012-1016.
5. Mahmud S, Franco E, and Aprikian A (2004). Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90, 93-99.
6. Dennis LK, Lynch CF, and Torner JC (2002). Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78-83.
7. Putzi MJ and De Marzo AM (2000). Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56, 828-832.
8. Quintar AA, Doll A, Leimgruber C, Palmeri CM, Roth FD, Maccioni M, and Maldonado CA (2010). Acute inflammation promotes early cellular stimulation of the epithelial and stromal compartments of the rat prostate. Prostate 70, 1153-1165.
9. Elkahwaji JE, Hauke RJ, and Brawner CM (2009). Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. Br J Cancer 101, 1740-1748.
10. Schmid JA and Birbach A (2008). IκB kinase beta (IKKß/IKK2/IKBKB)-a key molecule in signaling to the transcription factor NF-κB. Cytokine Growth Factor Rev 19, 157-165.
11. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, et al. (2007). IKKß suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-455.
12. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Chen CT, Huo L, Hsu MC, et al. (2009). KEAP1 E3 ligase-mediated downregulation of NF-κB signaling by targeting IKKß. Mol Cell 36, 131-140.
13. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, and Roy-Burman P (2001). Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101, 61-69.
14. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, et al. (2003). Pten dose dictates cancer progression in the prostate. PLoS Biol 1, E59.
15. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, et al. (2005). Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65, 5730-5739.
16. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, et al. (2003). Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221.
17. Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, Yoshida R, Wakeham A, Higuchi T, Fukumoto M, et al. (2001). T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523-534.
18. Sasaki Y, Derudder E, Hobeika E, Pelanda R, Reth M, Rajewsky K, and Schmidt-Supprian M (2006). Canonical NF-κB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 24, 729-739.
19. Barclay WW and Cramer SD (2005). Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate 63, 291-298.
20. Birbach A, Casanova E, and Schmid JA (2009). A Probasin-MerCreMer BAC allows inducible recombination in the mouse prostate. Genesis 47, 757-764.
21. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, and Marker PC (2005). Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 65, 10423-10430.
22. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, Cunha GR, Cardiff RD, Shen MM, and Abate-Shen C (2002). Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62, 2999-3004.
23. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, and Bieberich CJ (2010). Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol 176, 2259-2268.
24. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, et al. (2008). The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13, 519-528.
25. Vanaja DK, Cheville JC, Iturria SJ, and Young CY (2003). Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 63, 3877-3882.
26. Diamond MS, Staunton DE, de Fougerolles AR, Stacker SA, Garcia-Aguilar J, Hibbs ML, and Springer TA (1990). ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 111, 3129-3139.
27. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, et al. (2008). The nuclear factor-κB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68, 6762-6769.
28. Roy-Burman P, Wu H, Powell WC, Hagenkord J, and Cohen MB (2004). Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11, 225-254.
29. Richmond A (2002). Nf-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol 2, 664-674.
30. Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, Brosh R, Buganim Y, Goldfinger N, Klocker H, et al. (2009). Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epitheliasecreted IL-1. Carcinogenesis 30, 698-705.
31. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte ON, Liu X, and Wu H (2006). NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9, 367-378.
32. Supakar PC, Jung MH, Song CS, Chatterjee B, and Roy AK (1995). Nuclear factor κB functions as a negative regulator for the rat androgen receptor gene and NF-κB activity increases during the age-dependent desensitization of the liver. J Biol Chem 270, 837-842.
33. Delfino FJ, Boustead JN, Fix C, and Walker WH(2003).NF-κB andTNF-a stimulate androgen receptor expression in Sertoli cells. Mol Cell Endocrinol 201, 1-12.
34. Clement N, Glorian M, Raymondjean M, Andreani M, and Limon I (2006). PGE2 amplifies the effects of IL-1ß on vascular smooth muscle cell de-differentiation: a consequence of the versatility of PGE2 receptors 3 due to the emerging expression of adenylyl cyclase 8. J Cell Physiol 208, 495-505.
35. Leimgruber C, Quintar AA, Sosa LD, Garcia LN, Figueredo M, and Maldonado CA (2010). Dedifferentiation of prostate smooth muscle cells in response to bacterial LPS. Prostate 71, 1097-1107.
36. Deschner EE, Long FC, Hakissian M, and Herrmann SL (1983). Differential susceptibility of AKR, C57BL/6J, and CF1 mice to 1,2-dimethylhydrazine- induced colonic tumor formation predicted by proliferative characteristics of colonic epithelial cells. J Natl Cancer Inst 70, 279-282.
37. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, and Shen MM (2003). Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63, 3886-3890.
38. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, and Cunha GR (2000). Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 60, 6008-6017.
39. Cunha GR, Hayward SW, Dahiya R, and Foster BA (1996). Smooth muscle- epithelial interactions in normal and neoplastic prostatic development. Acta Anat (Basel) 155, 63-72.
40. Wong YC and Tam NN (2002). Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. Differentiation 70, 633-645.
41. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177-188.
42. Ramaswamy S, Ross KN, Lander ES, and Golub TR (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet 33, 49-54.